Ann: Update - Notification of buy-back - NEU, page-33

this is exactly the news of the last few hours. the suspended study has been withdrawn, so phase 2 PW to be redone perhaps with a new protocol or nothing. the reality of the facts is that here we have 2591 that for three phases 2 worked and there was an official statement, while for PW we expected from the company an explanation of the interruption of the trial more circumstantial than that date. from my point of view and evaluation, certain attitudes tend to be paid for on the market. obviously all waiting for what will happen at Soleno to which the approval evaluation has been postponed. evidently if it is positive, the sense of an antagonistic PW trial would be inappropriate. then wanting to tackle an analysis of the BB in progress it is a fact that jefferies is SYSTEMATICALLY buying and canceling almost 15% (maximum ceiling allowed for daily repurchase) since the first day of permitted operation. this gives us a clear feedback that neuren has a well-defined strategy of what it is doing in temporal, accounting and strategic terms. all in favor of a market that through these systematic facts, is able to calibrate the next moves to make with the complicity of the company. all my parameters are finding confirmation in supporting that the company is working to obtain a solid relative majority to support extraordinary operations on options to be converted and potentially a TO calibrated on a price per share clearly lower than the fanciful expectations that the retail that I read on this forum.